tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Citigroup Ceases to be Substantial Holder in Clarity Pharmaceuticals

Story Highlights
  • Citigroup Global Markets Australia Pty Limited has ceased to be a substantial holder in Clarity Pharmaceuticals.
  • The change affects Clarity’s shareholder structure and may influence market perceptions.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Citigroup Ceases to be Substantial Holder in Clarity Pharmaceuticals

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) is now available.

Clarity Pharmaceuticals Ltd. has announced that Citigroup Global Markets Australia Pty Limited and its related bodies corporate have ceased to be substantial holders of Clarity Pharmaceuticals as of September 19, 2025. This change in substantial holding reflects a decrease in relevant interest by Citibank, N.A. Sydney Branch, Citigroup Global Markets Australia Pty Limited, and Citigroup Global Markets Limited, impacting the company’s shareholder structure and potentially influencing market perceptions and investor relations.

The most recent analyst rating on (AU:CU6) stock is a Buy with a A$5.70 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.

More about Clarity Pharmaceuticals Ltd.

Average Trading Volume: 3,301,059

Technical Sentiment Signal: Buy

Current Market Cap: A$1.39B

For a thorough assessment of CU6 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1